Literature DB >> 17361223

Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts.

S Durual1, A Rideau, S Ruault-Jungblut, D Cossali, P Beris, V Piguet, T Matthes.   

Abstract

PU.1, a transcription factor of the ETS family, plays a pivotal role in normal hematopoiesis, and particularly in myeloid differentiation. Altered PU.1 function is possibly implicated in leukemogenesis, as PU.1 gene mutations were identified in some patients with acute myeloid leukemia (AML) and as several oncogenic products (AML1-ETO, promyelocytic leukemia-retinoic acid receptor alpha, FMS-like receptor tyrosine kinase 3 internal tandem duplication) are associated with PU.1 downregulation. To demonstrate directly a role of PU.1 in the blocked differentiation of leukemic blasts, we transduced cells from myeloid cell lines and primary blasts from AML patients with a lentivector encoding PU.1. In NB4 cells we obtained increases in PU.1 mRNA and protein, comparable to increases obtained with all-trans retinoic acid-stimulation. Transduced cells showed increased myelomonocytic surface antigen expression, decreased proliferation rates and increased apoptosis. Similar results were obtained in primary AML blasts from 12 patients. These phenotypic changes are characteristic of restored blast differentiation. PU.1 should therefore constitute an interesting target for therapeutic intervention in AML.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361223     DOI: 10.1038/sj.leu.2404645

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

1.  Pharmacological inhibition of the transcription factor PU.1 in leukemia.

Authors:  Iléana Antony-Debré; Ananya Paul; Joana Leite; Kelly Mitchell; Hye Mi Kim; Luis A Carvajal; Tihomira I Todorova; Kenneth Huang; Arvind Kumar; Abdelbasset A Farahat; Boris Bartholdy; Swathi-Rao Narayanagari; Jiahao Chen; Alberto Ambesi-Impiombato; Adolfo A Ferrando; Ioannis Mantzaris; Evripidis Gavathiotis; Amit Verma; Britta Will; David W Boykin; W David Wilson; Gregory Mk Poon; Ulrich Steidl
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

2.  PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia-initiating cells.

Authors:  Tianyuan Hu; Kiyomi Morita; Matthew C Hill; Yajian Jiang; Ayumi Kitano; Yusuke Saito; Feng Wang; Xizeng Mao; Kevin A Hoegenauer; Kazuhiro Morishita; James F Martin; P Andrew Futreal; Koichi Takahashi; Daisuke Nakada
Journal:  Blood       Date:  2019-07-03       Impact factor: 22.113

3.  Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents.

Authors:  Petra Bašová; Helena Paszeková; Lubomír Minařík; Martina Dluhošová; Pavel Burda; Tomáš Stopka
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

4.  PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation.

Authors:  Pavel Burda; Nikola Curik; Juraj Kokavec; Petra Basova; Dana Mikulenkova; Arthur I Skoultchi; Jiri Zavadil; Tomas Stopka
Journal:  Mol Cancer Res       Date:  2009-10-13       Impact factor: 5.852

5.  Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner.

Authors:  Samuel Milanovich; Jonathan Peterson; Jeremy Allred; Cary Stelloh; Kamalakannan Rajasekaran; Joseph Fisher; Stephen A Duncan; Subramaniam Malarkannan; Sridhar Rao
Journal:  Exp Hematol       Date:  2014-09-20       Impact factor: 3.084

6.  The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APL.

Authors:  Magali Humbert; Elena A Federzoni; Adrian Britschgi; Anna M Schläfli; Peter J M Valk; Thomas Kaufmann; Torsten Haferlach; Gerhard Behre; Hans-Uwe Simon; Bruce E Torbett; Martin F Fey; Mario P Tschan
Journal:  J Leukoc Biol       Date:  2013-09-13       Impact factor: 4.962

Review 7.  PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML.

Authors:  Tom Verbiest; Simon Bouffler; Stephen L Nutt; Christophe Badie
Journal:  Carcinogenesis       Date:  2015-03-06       Impact factor: 4.944

8.  RUNX1 induces DNA replication independent active DNA demethylation at SPI1 regulatory regions.

Authors:  Shubham Goyal; Takahiro Suzuki; Jing-Ru Li; Shiori Maeda; Mami Kishima; Hajime Nishimura; Yuri Shimizu; Harukazu Suzuki
Journal:  BMC Mol Biol       Date:  2017-04-04       Impact factor: 2.946

9.  Interference with RUNX1/ETO leukemogenic function by cell-penetrating peptides targeting the NHR2 oligomerization domain.

Authors:  Yvonne Bartel; Manuel Grez; Christian Wichmann
Journal:  Biomed Res Int       Date:  2013-06-25       Impact factor: 3.411

10.  PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.

Authors:  Nélida Inés Noguera; Maria Liliana Piredda; Riccardo Taulli; Gianfranco Catalano; Giulia Angelini; Girish Gaur; Clara Nervi; Maria Teresa Voso; Andrea Lunardi; Pier Paolo Pandolfi; Francesco Lo-Coco
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.